Patient-reported Quality of Life After Proton Beam Therapy for Prostate Cancer: The Effect of Prostate Size

Publication Date

2017

Journal Title

Clin Genitourin Cancer

Abstract

© 2017 Elsevier Inc. Micro-Abstract The present study assessed the effect of prostate gland size on patient-assessed quality of life (QOL) after definitive treatment of prostate adenocarcinoma with proton beam therapy. A larger prostate size, despite receiving a greater radiation dose, did not affect QOL at 6 months, providing further support that neoadjuvant cytoreductive treatments are unnecessary. Background In the present study, we assessed the effect of prostate gland size on patient-assessed genitourinary and gastrointestinal (GI) quality of life (QOL) after definitive treatment of prostate adenocarcinoma with proton beam therapy. Patients and Methods As a part of a prospective outcome tracking protocol, 81 patients treated at a single center between with proton beam therapy completed the Expanded Prostate Cancer Index Composite (EPIC) questionnaire before treatment and at the follow-up examinations. We reviewed the dosimetric data, reported as Vx(volume of organ receiving x Gy), and patient-reported QOL at 6 months. Genitourinary QOL was assessed using the American Urological Association symptom score and EPIC urinary domain score. GI QOL was assessed using the EPIC GI domain score. Results Larger prostate glands were associated with greater bladder V70(P 95%) maintained. Patients with larger prostates did not have a greater change in their American Urological Association symptom index scores (< 30 cm3, +2.3; 30-49 cm3, +3.2; ≥ 50 cm3, 0.2; P =.06) or urinary domain score (< 30 cm3, −3.6; 30-49 cm3, −3.1; ≥ 50 cm3, +3.8; P =.76) at 6 months after treatment. Also, prostate size was not associated with a change in the EPIC GI domain score at 6 months after treatment (< 30 cm3, −3.7; 30-49 cm3, −1.1; ≥ 50 cm3, −0.55; P =.67). Conclusion Definitive proton beam therapy for prostate cancer to a dose of 79.2 Gy resulted in excellent patient-reported urinary and GI QOL, independently of the baseline prostate size. This single-institution finding should be tested further in a multi-institutional study to confirm the potential limited role of androgen deprivation therapy.

Volume Number

15

Issue Number

6

Pages

704 - 710

Document Type

Article

Status

Faculty

Facility

School of Medicine

Primary Department

Radiation Medicine

PMID

28412047

DOI

10.1016/j.clgc.2017.03.005

For the public and Northwell Health campuses

Share

COinS